C. Robalo Cordeiro (Coimbra, Portugal), C. Saltini (Rome, Italy)
Dermato-pulmonary syndrome associated with MDA-5 antibodies: Report of the first French series
Y. Uzunhan, H. Nunes, G. Leroux, D. Saadoun, H. Devilliers, F. Cohen-Aubart, B. Hervier, J. Wipff, J. L. Charuel, S. Audia, B. Bonnotte, S. Barete, A. Rigolet, S. Herson, M. Miyara, Y. Allenbach, O. Benveniste (Bobigny, Paris, Dijon, France)
|  |
Scleroderma lung disease: Detection of pulmonary hypertension using pulmonary function tests is problematic in patients with emphysema
K. Antoniou, G. Margaritopoulos, D. Hansell, S. Desai, T. Maher, E. Renzoni, N. Siafakas, A. Wells (Heraklion, Greece; London, United Kingdom)
| |
B cell activating factor belonging to the TNF family might be a useful biomarker in interstitial lung diseases associated with connective tissue diseases
T. Hamada, T. Kumamoto, A. Harumatsu, K. Mizuno, T. Samukawa, I. Higashimoto, M. Watanabe, H. Inoue (Kagoshima, Japan)
|  |
A clinicopathological review of interstitial pneumonia with marked IgG4 positive plasma cells infiltration
S. Ikeda, T. Baba, M. Arita, T. Takemura, T. Ogura, T. Ishida (Kurashiki, Yokohama, Hiroo, Shibuya-ku, Japan)
| |
Anti periplakin antibodies in connective tissue-associated lung fibrosis
C. Taillé, M. Neuville, S. Grootenboer-Mignot, P. Dieudé, Y. Allanore, S. Chollet-Martin, B. Crestani (Paris, France)
| |
Scleroderma lung disease: A scleroderma physiologic index (SPI) derived from lung physiology and oxygen saturation
K. Antoniou, D. Hansell, N. Goh, K. Samara, E. Renzoni, M. Toby, N. Siafakas, A. Wells (Heraklion, Greece; London, United Kingdom)
| |
The value of biomarkers in the rheumatoid arthritis related interstitial pneumonia
Y. S. Lee, H. C. Kim, C. K. Lee, M. Y. Kim, S. Han, F. B. Carol, D. S. Kim (Busan, Seoul, Republic Of Korea; Pittsburgh, United States Of America)
| |
Rituximab therapy for interstitial lung disease in patients with antisynthetase syndrome
L. Tabeze, R. Borie, J. E. Kahn, E. Catherinot, B. Crestani, L. J. Couderc (Paris, Suresnes, France)
| |
Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP)
M. Korfei, I. Henneke, P. Markart, D. Von Der Beck, C. Ruppert, P. Mahavadi, W. Klepetko, L. Fink, S. Meiners, O. Krämer, W. Seeger, C. Vancheri, A. Guenther (Giessen, Munich, Jena, Greifenstein, Germany; Vienna, Austria; Catania, Italy)
| |
Analysis of multicentric Castleman’s disease (MCD) with pulmonary lesions
S. Ikushima, Y. Terasaki, A. Hebisawa, T. Johko, F. Sakai, N. Nishimoto, T. Ogura, Y. Ohta, H. Ishii, S. Matsui, H. Yamamoto, Y. Ichimura, M. Ujita, T. Kawamura, M. Bando, H. Ishimoto, S. Izumi, N. Hata, K. Tomii, I. Owan, H. Kimura, Y. Komase, Y. Matsuzawa, M. Arita, A. Shiraki (Tokyo, Itami, Saitama, Osaka, Kanagawa, Toyama, Matsumoto, Chiba, Shibukawa, Himeji, Shimotsuke, Kitakyushyu, Kawaguchi, Kobe, Okinawa, Nara, Yokohama, Sakura, Kurashiki, Ogaki, Japan)
| |
Incidence of interstitial lung disease (ILD) and risk factors for developing ILD: A final analysis of a large-scale erlotinib Japanese surveillance study in non-small-cell lung cancer (NSCLC)
H. Taniguchi, S. Kudoh, M. Ando, Y. Ohe, K. Nakagawa, H. Arakawa, M. Ebina, Y. Inoue, A. Gemma, M. Kusumoto, K. Kuwano, F. Sakai, T. Johkoh, Y. Fukuda, Y. Kiyohara, N. Yamazaki, A. Seki, M. Fukuoka (Seto, Tokyo, Nagoya, Kashiwa, Osaka, Tochigi, Sendai, Saitama, Hyogo, Shizuoka, Japan)
| |
Serum heat shock protein 47 levels in patients with drug induced lung diseases
T. Kakugawa, S. I. Yokota, Y. Ishimatsu, S. Nakashima, S. Hara, N. Sakamoto, H. Kubota, M. Mine, Y. Matsuoka, H. Mukae, K. Nagata, S. Kohno (Nagasaki, Sapporo, Kyoto, Akita, Kitakyushu, Japan)
| |
Levels of antimicrobial peptide LL-37 in BALF and ELF from patients with pulmonary fibrosis
M. Lemieszek, M. Golec, C. Reichel, J. Buczkowski, B. Mackiewicz, C. Skórska, A. Góra, J. Dutkiewicz, R. Ziesche, J. Milanowski (Lublin, Poland; Vienna, Austria)
| |
Rituximab in severe, treatment-refractory interstitial lung disease
R. Abdullah, D. Ming, G. Keir, T. Maher, A. Wells, E. Renzoni (London, United Kingdom)
| |
Clinical manifestations of systemic sclerosis (SS) accompanied with pulmonary involvement
D. Petrova, Y. Shoikhet, S. Berestov, A. Dorokhov (Barnaul, Russian Federation)
| |
KL-6, SP-D and MMP-7 as serum biomarkers for early detection of interstitial lung diseases
N. Ishikawa, K. Yoshioka, Y. Horimasu, H. Iwamoto, S. Ohshimo, N. Hattori, N. Kohno (Hiroshima, Japan)
| |
Clinical manifestation and prognostic factor in anti-aminoacyl-tRNA synthetase autoantibodies-associated interstitial lung disease
C. Nishio, H. Tomioka, R. Sekiya, S. Yamashita, T. Kaneda, Y. Kida, M. Kaneko, H. Fujii, K. Ishihara (Kobe, Japan)
| |
Characteristics and predictors of outcome in rheumatoid arthritis related ILD
D. Middleton, H. Sarah, M. David, D. Owen, B. Neil (Aberdeen, United Kingdom)
| |